Loading clinical trials...
Loading clinical trials...
This is a Phase I/II study to evaluate the safety profile, tolerability, pharmacokinetics and pharmacodynamics following daily oral doses of 50 to 200 mg of BMS-754807 in combination with trastuzumab ...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Bristol-Myers Squibb
NCT04541381 · Gastrointestinal Cancer, Head and Neck Cancer, and more
NCT05468034 · Breast Cancer, Indolent Metastatic Breast Cancer
NCT03137095 · Cancer Related Cognitive Difficulties, Breast Cancer Female
NCT07040891 · Breast Cancer
NCT07547774 · Breast Cancer, Postoperative Pain, and more
Local Institution
Kurralta Park, South Australia
Local Institution
Frankston, Victoria
Local Institution
Geelong, Victoria
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions